What is Gallant?
Gallant operates at the intersection of biotechnology and veterinary medicine, specializing in the development of regenerative therapies designed to restore health at the source. The company's core competency lies in its ability to manufacture and commercialize stem cell treatments that address complex, underlying pathologies in pets. By leveraging deep expertise in clinical development and manufacturing, Gallant is effectively creating a new category of veterinary medicine that prioritizes long-term wellness over palliative care. Their market position is defined by a commitment to scientific rigor and the democratization of regenerative medicine, making high-end therapeutic interventions accessible to a broader range of veterinary practices and pet owners.
How much funding has Gallant raised?
Gallant has raised a total of $28.2M across 2 funding rounds:
Other Financing Round
$18M
Private Equity
$10.2M
Other Financing Round (2025): $18M with participation from NovaQuest Capital Management and Digitalis Ventures
Private Equity (2025): $10.2M, investors not publicly disclosed
Key Investors in Gallant
NovaQuest Capital Management
A premier investment firm specializing in biopharma and life sciences, known for pioneering product finance solutions that support clinical trials and commercial launches.
Digitalis Ventures
A multidisciplinary investment group that engineers solutions for unmet health needs by providing capital and operational expertise to biotechnology and technology-enabled enterprises.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Gallant?
With the recent influx of capital, Gallant is well-positioned to advance its clinical pipeline and optimize its manufacturing capabilities. The strategic focus will likely shift toward scaling the commercialization of its existing therapies while simultaneously investing in research and development to broaden its therapeutic reach. As the company navigates this major enterprise-level funding phase, the primary objective remains the validation of its regenerative platform through expanded clinical trials and the establishment of a robust supply chain. This growth trajectory suggests that Gallant is preparing to solidify its leadership in the animal health biotech space, potentially setting the stage for future partnerships or market expansion initiatives that will further integrate regenerative solutions into standard veterinary practice.
See full Gallant company page
